Myasthenia gravis and azathioprine treatment: Adverse events related to thiopurine S-methyl-transferase (TPMT) polymorphisms

被引:13
作者
Lorenzoni, Paulo Jose [1 ]
Kamoi Kay, Claudia Suemi [1 ]
Zanlorenzi, Marcelo Farago [1 ]
Ducci, Renata Dal-Pra [1 ]
Werneck, Lineu Cesar [1 ]
Scola, Rosana Herminia [1 ]
机构
[1] Univ Fed Parana UFPR, Hosp Clin, Dept Internal Med, Serv Neuromuscular Disorders,Div Neurol, Curitiba, Parana, Brazil
关键词
Myasthenia gravis; Thiopurine-methyl-transferase; Azathioprine; Pharmacogenetics; Therapeutics; Adverse event; Genotype; INFLAMMATORY-BOWEL-DISEASE; METHYLTRANSFERASE ALLELES; GENE POLYMORPHISM; PHARMACOGENETICS; PREVALENCE; VARIANTS; FREQUENCY; TOXICITY;
D O I
10.1016/j.jns.2020.116734
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Azathioprine (AZA) is the most common immunosuppressive drug used to treat myasthenia gravis (MG). To analyses the prevalence of thiopurine S-methyl-transferase (TPMT) genotypes and their association with adverse events due to azathioprine therapy in MG patients. Allele-specific polymerase chain reaction (PCR) and PCR with restriction fragment length polymorphism (RFLP) analysis were carried out to determine the prevalence of the most common TPMT genotypes (*2, *3A, *3B and *3C) in 50 MG patients from Southern Brazilian. The frequency of adverse reactions due to azathioprine therapy was analysed and correlated with different genotypes groups. The prevalence of TPMT gene variants was 12%. The allelic frequency of variant TPMT*2 (C238G), TPMT*3A (G460A/A719G), TPMT*3B (G460A), and TPMT*3C (A719G) genotypes was 1, 3, 2 and 1%, respectively. Adverse events occurred in 44%, of MG patients, of which 86% were minor and 14% were major. One patient, who presented a major adverse event (bone marrow suppression), was homozygous for the TPMT*3A genotype. Our study estimated the prevalence of TPMT genotypes for Brazilian MG patients. The profile of TPMT genotypes was different from other Brazilian populations. Hardy-Weinberg equilibrium and allelic frequencies of TPMT*3A and TPMT*3B, respectively, were different than expected, a finding that suggests a possible founder effect. Major adverse events were statistically significant for TPMT genotypes compared to wild-type. Although TPMT genotype has been associated with AZA-related adverse events, since no statistically significant difference among wild-type and other TPMT genotypes for minor adverse events, our study supports the view that TPMT genotype alone is not enough to adequately personalise the AZA therapy in MG patients. In conclusion, these results were important to characterise the prevalence of TPMT gene variants in MG patients treated with AZA and correlate the adverse events of this therapy in a real-world outpatient clinic from Southern Brazil.
引用
收藏
页数:5
相关论文
共 30 条
[1]  
Adehin A., 2017, POL ANN MED, V24, P144, DOI [10.1016/j.poamed.2016.06.007, DOI 10.1016/J.POAMED.2016.06.007]
[2]   Thiopurine methyltransferase alleles in British and Ghanaian populations [J].
Ameyaw, MM ;
Collie-Duguid, ESR ;
Powrie, RH ;
Ofori-Adjei, D ;
McLeod, HL .
HUMAN MOLECULAR GENETICS, 1999, 8 (02) :367-370
[3]   Thiopurine methyltransferase polymorphisms in a Brazilian population [J].
Boson, WL ;
Romano-Silva, MA ;
Correa, H ;
Falcao, RP ;
Teixeira-Vidigal, PV ;
De Marco, L .
PHARMACOGENOMICS JOURNAL, 2003, 3 (03) :178-182
[4]   Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype [J].
Broekman, M. M. T. J. ;
Coenen, M. J. H. ;
Wanten, G. J. ;
van Marrewijk, C. J. ;
Klungel, O. H. ;
Verbeek, A. L. M. ;
Hooymans, P. M. ;
Guchelaar, H. -J. ;
Scheffer, H. ;
Derijks, L. J. J. ;
Wong, D. R. ;
de Jong, D. J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (10) :953-963
[5]   Thiopurine-methyltransferase variants in inflammatory bowel disease: Prevalence and toxicity in Brazilian patients [J].
Carvalho, Ana Teresa P. ;
Esberard, Barbara C. ;
Froes, Renata S. B. ;
Rapozo, Davy C. M. ;
Grinman, Ana B. ;
Simao, Tatiana A. ;
Santos, Juliana C. V. C. ;
Carneiro, Antonio Jose V. ;
Ribeiro-Pinto, Luis Felipe ;
de Souza, Heitor S. P. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (12) :3327-3334
[6]   Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations [J].
Chang, JG ;
Lee, LS ;
Chen, CM ;
Shih, MC ;
Wu, MC ;
Tsai, FJ ;
Liang, DC .
PHARMACOGENETICS, 2002, 12 (03) :191-195
[7]   A New Thiopurine S-Methyltransferase Haplotype Associated With Intolerance to Azathioprine [J].
Colleoni, Lara ;
Kapetis, Dimos ;
Maggi, Lorenzo ;
Camera, Giorgia ;
Canioni, Eleonora ;
Cavalcante, Paola ;
de Rosbo, Nicole Kerlero ;
Baggi, Fulvio ;
Antozzi, Carlo ;
Confalonieri, Paolo ;
Mantegazza, Renato ;
Bernasconi, Pia .
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (01) :67-74
[8]   The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations [J].
Collie-Duguid, ESR ;
Pritchard, SC ;
Powrie, RH ;
Sludden, J ;
Collier, DA ;
Li, T ;
McLeod, HL .
PHARMACOGENETICS, 1999, 9 (01) :37-42
[9]   Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece [J].
Coucoutsi, Constantina ;
Emmanouil, George ;
Goulielmos, George ;
Sfakianaki, Ourania ;
Koutroubakis, Ioannis E. ;
Kouroumalis, Elias A. .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (11) :1284-1289
[10]   Distribution of TPMT risk alleles for thioupurine toxicity in the Israeli population [J].
Efrati, Edna ;
Adler, Lior ;
Krivoy, Norberto ;
Sprecher, Eli .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (03) :257-262